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The mitochondrial H+-ATP synthase synthesizes
most of cellular ATP requirements by oxidative
phosphorylation (OXPHOS). The ATPase Inhibitory
Factor 1 (IF1) is known to inhibit the hydrolase activity
of theH+-ATPsynthase in situations that compromise
OXPHOS. Herein, we demonstrate that phosphoryla-
tion of S39 in IF1 by mitochondrial protein kinase A
abolishes its capacity to bind the H+-ATP synthase.
Only dephosphorylated IF1 binds and inhibits both
the hydrolase and synthase activities of the enzyme.
The phosphorylation status of IF1 regulates the flux
of aerobic glycolysis and ATP production through
OXPHOS in hypoxia and during the cell cycle. De-
phosphorylated IF1 is present in human carcinomas.
Remarkably, mouse heart contains a large fraction of
dephosphorylated IF1 that becomes phosphorylated
and inactivated upon in vivo b-adrenergic stimula-
tion. Overall, we demonstrate the essential function
of the phosphorylation of IF1 in regulating energy
metabolism and speculate that dephosho-IF1 might
play a role in signaling mitohormesis.
INTRODUCTION
The mitochondrial H+-ATP synthase (Walker, 2013) synthesizes
most of the ATP that is needed to sustain cellular activity in
normal differentiated cells. This protein complex also partici-
pates in the execution of cell death (Sa´nchez-Arago´ et al.,
2013a) and in shaping mitochondrial ultrastructure (Paumard
et al., 2002). In mitochondria, futile ATP hydrolysis by the H+-
ATP synthase is inhibited by the ATPase Inhibitory Factor 1
(IF1) that reversibly binds to the enzyme (Walker, 2013). The
structure of the inhibited F1-ATPase complex with bound IF1
in the presence of ATP has been solved (Bason et al., 2014;
Cabezo´n et al., 2003). Residues 1–37 in the mature IF1 stabilize
the binding of the inhibitor to the ab-interface in the F1-ATPase
domain, blocking rotary catalysis (Cabezo´n et al., 2003). TheCell Repexpression of IF1 varies greatly between different normal human
tissues and is highly overexpressed in some prevalent human
carcinomas (Sa´nchez-Arago´ et al., 2013b; Sa´nchez-Cenizo
et al., 2010). The physiological function ascribed to IF1 is to
inhibit the hydrolase activity of the H+-ATP synthase when
mitochondria becomes de-energized, such as in hypoxic cells
(Campanella et al., 2008; Gledhill et al., 2007). However, data
obtained in cancer (Formentini et al., 2012; Sa´nchez-Arago´
et al., 2013b; Sa´nchez-Cenizo et al., 2010) and in stem cells
(Sa´nchez-Arago´ et al., 2013c), as well as in mouse models over-
expressing an active IF1 in neurons (Formentini et al., 2014),
support that, in the in vivo context, IF1 also inhibits the synthase
activity of the H+-ATP synthase. Moreover, the IF1-mediated
inhibition of the enzyme has been shown to trigger amild reactive
oxygen species (ROS) signal that promotes metabolic reprog-
ramming and nuclear preconditioning aimed at preventing cell
death (Formentini et al., 2012; Sa´nchez-Arago´ et al., 2013b),
two events that favor neuroprotection in vivo after challenging
the brain of transgenic IF1-expressing mice with an excitotoxic
insult (Formentini et al., 2014). In line with these findings,
silencing of IF1 has been shown to ameliorate severe mitochon-
drial respiratory chain dysfunctions (Chen et al., 2014).
Despite the main role of IF1 in pathophysiology, the mecha-
nisms that regulate its activity in vivo are basically unknown.
Previous phosphoproteomic analyses have reported that IF1 is
phosphorylated in S39 in skeletal muscle (Zhao et al., 2011)
and cancer cell lines (Sharma et al., 2014; Zhou et al., 2013).
The phosphorylation of human IF1 in S63 has also been reported
(Christensen et al., 2010; Zhou et al., 2013). In this study, we
show that activation of PKA phosphorylates IF1 and that phos-
phorylation of S39 in IF1 interferes with its ability to interact
with the H+-ATP synthase. Remarkably, phosphorylation of IF1
affects both the synthetic and hydrolytic activities of the enzyme
and contributes to in vivo metabolic reprogramming for adapta-
tion to different physiological contexts.
RESULTS
IF1 Is Phosphorylated in Some Human Cancer Cell Lines
Protein extracts of colon (HCT116), cervix (HeLa), breast
(BT549), lung (HOP62), and ovarian (OVCAR8) cancer cell linesorts 12, 2143–2155, September 29, 2015 ª2015 The Authors 2143
Figure 1. PKA Phosphorylates IF1
(A) Proteins from HCT116, HeLa, BT549, HOP62,
and OVCAR8 cells were fractionated on 2D gels
and blotted against anti-b-F1-ATPase (b-F1) and
anti-IF1.
(B) Cellular proteins from HCT116 cells were
fractionated and treated (+) or not (-) with CiP.
(C) Immunoprecipitated (IP) IF1 from HCT116 and
SHSY5Y cellular extracts were treated (+) or not (-)
with CiP and blotted with anti-phospho-Ser anti-
body. Non-specific immunoglobulin G (IgG) was
included as control.
(D) HCT116 cells were treated with the PKA in-
hibitor H89 or PKI, or with db-cAMP, and the
cellular extracts were fractionated on 2D gels. In
(A), (B), and (D), the pI range of the strips and that
of the focused proteins are indicated under the
blots.
(E) HCT116 cells treated with db-cAMP, H89, or
PKI revealed no changes in the steady-state
content of IF1 when compared to untreated con-
trol cells (CRL).
(F) BT549 cells were left untreated (CRL) or treated
with H89, db-cAMP, or Frsk, and the phosphory-
lated IF1 was revealed by incubation with the PKA
phospho-serine residue antibody in the immuno-
precipitated IF1.fractionated on two-dimensional (2D) gels revealed the exis-
tence of protein isoforms of IF1 that differed in the isoelectric
point (pI) depending on the cell line considered (Figure 1A).
Focusing of b-F1-ATPase was used as a control (Figure 1A). In
breast and lung cancer cells, the main isoform of IF1 has a pI
of 8.9, close to the theoretical pI of the protein. In contrast, in
colon, cervix, and ovarian cancer cells, IF1 appeared as two
main isoforms, with pIs in the range of 7.6–8.1 (Figure 1A). The
existence of more acidic isoforms differing in the pI of the protein
suggested the covalent modification of IF1 by phosphorylation.
This was confirmed in HCT116 cells by treatment of cell lysates
with CiP (calf-intestinal alkaline phosphatase), which promoted
the shift of IF1 to the basic region of the gel (pI = 8.9) (Figure 1B).
Immunoprecipitation experiments with anti-IF1 of cellular
extracts preincubated or not with CiP and blotting with anti-
bodies against anti-phospho-Ser confirmed the presence of
phosphorylated serines in IF1 in HCT116 and SHSY5Y cells
(Figure 1C).2144 Cell Reports 12, 2143–2155, September 29, 2015 ª2015 The AuthorsIF1 Is Phosphorylated by PKA
Cyclic AMP (cAMP)-dependent protein
kinase A (PKA) is a predicted kinase
that might be involved in the phosphory-
lation of IF1 (NetPhos 2.0; PhosphoMotif
Finder). PKA is known to regulate mito-
chondrial respiration through phosphor-
ylation of cytochrome c oxidase (Acin-
Perez et al., 2009, 2011) and/or complex
I (Papa et al., 2008). To this end, HCT116
cells were treated with different activa-
tors or inhibitors of PKA, and the IF1
isoforms were analyzed on 2D gels(Figure 1D). Treatment of the cells with two different inhibitors
of the activity of PKA—the pseudosubstrate inhibitory peptide
PKI (protein kinase inhibitor) or the competitive inhibitor H89
(Figure 1D)—revealed IF1 in its dephosphorylated state (pI =
8.9) (Figure 1D). In contrast, when cells were treated with the
membrane-permeable PKA activator dibutyryl cAMP (db-
cAMP), all IF1 was phosphorylated (pI = 7.6–8.1) (Figure 1D)
in the absence of relevant changes on the content of IF1
(Figure 1E).
Western blots of immunoprecipitated IF1 from BT549 cells,
which showed most of IF1 in its dephosphorylated state (pI =
8.9) (Figure 1A), revealed no immunoreactivity toward the
specific PKA anti-phospho-Ser antibody when the cells were
left untreated or treated with the PKA inhibitor H89 (Figure 1F).
In contrast, phosphorylated IF1 was immunoprecipitated from
BT549 cells treated with db-cAMP or with the adenylyl cyclase
activator forskolin (Frsk) (Figure 1F), further supporting the differ-
ential regulation of IF1 phosphorylation by PKA in different
Figure 2. Dephospho-IF1 Binds and Inhibits the Hydrolase and Synthase Activities of the H+-ATP Synthase
(A) HCT116 cells treated with H89, PKI, or db-cAMP or left untreated (CRL) were immunoprecipitated with anti-b-F1-ATPase, and the co-immunoprecipitated IF1
was identified by western blotting.
(B) Same as in (A), but immunoprecipitation was carried out with anti-F1-ATPase antibody.
(C) BN immunoblot analysis fromHCT116 cells left untreated (CRL) or treated with H89 or Frsk. Themigration of Complex V (FoF1) and IF1 is identified by reaction
against anti-b-F1-ATPase and anti-IF1 antibodies, respectively. Migration of molecular massmarkers is indicated. The histograms show the IF1/bF1 ratio of three
different experiments.
(D) Hydrolase activity of the H+-ATP synthase in isolated mitochondria from untreated HCT116 (CRL, black) and from H89 (green)-, and db-cAMP (blue)-treated
cells. Where indicated, 30 mM OL was added. A340, absorbance at 340 nm.
(E) Rates of ATP production in isolated mitochondria from HCT116 cells.
(F) Rates of ATP production in digitonin-permeabilized HCT116 cells.
Bars indicate the mean ± SEM of four to five different samples. *p < 0.05 when compared to CRL by Student’s t test.cancer cells (Figure 1A). In vitro PKA phosphorylation assays of
IF1 resulted unsuccessfully (Figures S1A and S1B), suggesting
that phosphorylation of IF1 might require scaffolding proteins.
Dephosphorylation of IF1 Promotes Its Binding to the
F1-ATPase Complex
First, we studied the effect of IF1 phosphorylation on its capacity
to bind the F1-ATPase complex (Figure 2A). Co-immunoprecip-
itation experiments of IF1 with a polyclonal antibody against the
b-F1-ATPase subunit were carried out in HCT116 cells that were
left untreated or treated with inhibitors (H89 and PKI) or the
activator (db-cAMP) of IF1 phosphorylation (Figure 2A). Basal
untreated HCT116 cells or cells treated with db-cAMP showed
no co-immunoprecipitation of IF1 with the b subunit of theCell RepH+-ATP synthase (Figure 2A). In contrast, cells treated with
H89 and PKI—and, hence, with most of IF1 in its dephosphory-
lated state—showed high levels of IF1 co-immunoprecipitated
with b-F1-ATPase (Figure 2A). Similar experiments were carried
out using another antibody against the F1-ATPase complex,
confirming that the dephosphorylation status of IF1 is required
for its interaction and binding to theH+-ATP synthase (Figure 2B).
Interestingly, we noted that, in some experiments, a low amount
of IF1 could be immunoprecipitated from control HCT116 cells
(compare CRL in Figures 2A and 2B), suggesting a potential
regulation of the phosphorylation of IF1 upon cellular conditions
(discussed later). Consistent with these findings, Blue Native
(BN) gels of mitochondrial membrane proteins from HCT116
cells revealed that the amount of IF1 bound to the ATP synthaseorts 12, 2143–2155, September 29, 2015 ª2015 The Authors 2145
was increased in cells treated with H89 when compared to
control or Frsk-treated cells (Figure 2C).
Dephosphorylated IF1 Inhibits Both the Synthase and
Hydrolase Activities of the H+-ATP Synthase
HCT116 cells were incubated with H89 or db-cAMP or were left
untreated prior to mitochondrial extraction to study the effect of
IF1 phosphorylation on the hydrolase and synthase activities of
the enzyme (Figures 2D and 2E). Mitochondria from H89-treated
cells containing dephosphorylated IF1 showed a diminished
ATP hydrolase activity when compared to controls (Figure 2D),
suggesting that phosphorylation of IF1 prevents its inhibitory
action on the hydrolase. db-cAMP-treated cells displayed
almost the same ATP hydrolase activity as that of control un-
treated cells (Figure 2D). Likewise, determination of the ATP syn-
thetic activity of the enzyme in isolated mitochondria revealed
that the production of ATP when IF1 is in its dephosphorylated
state (H89 in Figure 2E) is diminished when compared to control
mitochondria and similar to that of mitochondria incubated with
oligomycin (OL) (Figure 2E). A slightly enhanced ATP synthetic
capacity was observed in cells treatedwith db-cAMP (Figure 2E).
Moreover, the ATP synthetic activity of the enzyme assessed in
digitonin-permeabilized HCT116 cells treated with H89 showed
a significant inhibition when compared to control cells (Fig-
ure 2F). In contrast, cells treated with db-cAMP significantly
increased the rate of ATP synthesis in this situation (Figure 2F).
Overall, the results support that dephosphorylated IF1 binds
and inhibits the H+-ATP synthase both in hydrolytic and synthetic
modes, whereas phosphorylated IF1 is unable to bind and,
hence, to interfere with the normal and reverse activities of the
H+-ATP synthase.
Phosphorylation of Serine 39 Is the Switch-Off Button
To identify the potential serine residues involved in regulating the
activity of IF1 on the H+-ATP synthase we created the phospho-
mutant (S27A, S39A, and S63A) and phospho-mimetic (S27E,
S39E, and S63E) point mutants of the serine residues present
in the mature IF1 protein (Figure S1C; Table S1). To comply
with the nomenclature of previous phosphoproteomic studies,
the mutants are defined by residue number in the full-length
IF1 sequence unless explicitly mentioning the residue in the
mature protein. Transfection of HCT116 cells with a plasmid en-
coding the wild-type version of IF1 triggered a large overexpres-
sion of the dephosphorylated protein (Figure 3A) and the partial
inhibition of the synthesis of ATP when compared to control cells
transfected with the empty vector (EV) (Figure 3B). It should be
noted that the cellular stress triggered by transfection already
promoted dephosphorylation of IF1 (EV; Figure 3A). Analysis of
the effect of the expression of the phospho-mutant and phos-
pho-mimetic constructs on ATP synthesis assessed in permea-
bilized cells revealed that only S39A had a significant negative
effect on the activity when compared to the wild-type IF1 or to
the corresponding phospho-mimetic S39E, which presented a
similar ATP output to EV-transfected cells (Figure 3B). Consis-
tent with a role for the phosphorylation of S39 in regulating
IF1 activity, we observed that Frsk-treated cells overexpressing
S39A did not relieve the inhibition on the ATP synthase activity
(Figure 3C), as it occurs in cells expressing wild-type IF12146 Cell Reports 12, 2143–2155, September 29, 2015 ª2015 The A(Figure 3C). As expected, cells expressing S39E showed higher
ATP synthase activities than cells expressing wild-type IF1,
further revealing no major differences when incubated with
H89 or Frsk (Figure 3C).
As shown earlier (Figures 2A and 2B), the inhibition of the ATP
synthase correlated with the binding of IF1 to F1-ATPase as re-
vealed by co-immunoprecipitation of the inhibitory S39A mutant
with b-F1-ATPase (Figure 3D) and the negligible pull-down of
the non-inhibitory S39E in the same situation (Figure 3D). Co-
immunoprecipitation of S39A and b-F1-ATPase also occurred
when cells were treated with Frsk (Figure 3E). Moreover, BN
gels also showed that interaction with the ATP synthase only oc-
curs when the S39Amutant is being expressed (Figure 3F). Over-
all, the results support that phosphorylation of S39 is a main
player in preventing the binding and inhibition of IF1 on the
ATP synthase.
Dephosphorylated IF1 Inhibits OXPHOS and Enhances
Aerobic Glycolysis
Consistent with previous findings showing that PKA-mediated
phosphorylation affects the activity of mitochondrial respiratory
complexes, we observed that cells treated with H89 and PKI
had reduced respiratory rates (Figure 4A). OL-sensitive respira-
tion (OSR) is a measure of the activity of the H+-ATP synthase.
To verify that the effect of PKA on OSR was mainly due to IF1
and not to the effect of PKA on other proteins of the OXPHOS
(oxidative phosphorylation) system, we performed the same
experiments but in silenced IF1 cells (Figure 4B). The results
revealed that silencing of IF1 reverted the effect of H89 on
OSR (Figure 4B), supporting that dephosphorylated IF1 is inhib-
iting the synthetic activity of the H+-ATP-synthase in cells in
culture.
The inhibition of OXPHOS by IF1 is balanced by a burst in aer-
obic glycolysis (Sa´nchez-Cenizo et al., 2010). Hence, we deter-
mined the glycolytic flux by measuring the initial rate of lactate
production (Figure 4C). Aerobic glycolysis was upregulated in
cells treated with PKA inhibitors and was not affected when
cells were incubated with db-cAMP (Figure 4C). Silencing of
IF1 prior treatment with both PKA inhibitors also resulted in
blunting the upregulation of aerobic glycolysis (Figure 4D). Over-
all, we show that the phosphorylation of IF1 determines its bio-
logical activity and, therefore, that its regulationmediates cellular
reprogramming of energy metabolism.
IF1 and the Flux of Energy Provision Pathways
We compared the phosphorylation of IF1 of HCT116 cells
growing in the presence of OL versus that of cells growing in
the presence of 2-deoxyglucose (2DG) (Figure 5A), which are
known to regulate the flux of energy metabolism through glycol-
ysis and OXPHOS, respectively (Figure 5A) (Sa´nchez-Arago´
et al., 2010). Despite the presence of OL, we observed that a
fraction (30%) of IF1 becomes dephosphorylated when
HCT116 cells are incubated with OL (Figure 5A). Incubation of
the cells with 2DG, which upregulates OXPHOS, does not signif-
icantly affect the phosphorylation of IF1 (Figure 5A). Similar
experiments in BT549 cells that have most of IF1 dephosphory-
lated in basal state (Figure 1A) revealed the opposite situation
showing a shift of a fraction of IF1 (30%) toward a moreuthors
Figure 3. Phosphorylation of S39 Regulates the Activity of IF1
(A) HCT116 cells non-transfected or transfected with EV or with pIF1 were treated with H89 or Frsk and fractionated on 2D gels.
(B) ATP synthase activity in permeabilized HCT116 cells expressing wild-type IF1 (pIF1, red), IF1 phospho-mutant (pS27A, pS39A, and pS63A; green), or IF1
phospho-mimetic (pS27E, pS39E, and pS63E; blue) constructs.
(C) Same as in (B), but treated with H89 or Frsk.
(D and E) HCT16 cells transfected with EV, pS39A, or pS39E non-treated (D) or treated with H89 or Frsk (E) were immunoprecipitated (IP) with anti-F1-ATPase,
and the co-immunoprecipitated IF1 was identified.
(F) BN immunoblot of mitochondrial membrane proteins fromHCT116 cells transfected with pIF1, pS39A, or pS39E. Themigration of Complex V (FoF1) and IF1 is
shown, along with input levels of both proteins.
In (B) and (C), error bars indicate the mean ± SEM of four to five different samples. *p < 0.05, when compared to CRL by Student’s t test. ns, non-significant.phosphorylated state when the cells are incubated in the pres-
ence of 2DG (Figure 5B). Consistently, changes in the phosphor-
ylation status of IF1 in BT549 cells also correlated with an
increase in the activity of OXPHOS, as revealed by OSR and
the reduction of aerobic glycolysis (Figure 5B).
IF1 and Progression through the Cell Cycle
Cell cycle progression is known to affect the relative activity of
the main energy provision pathways of the cell (Chen et al.,
2007). Whereas the G1 phase is largely dependent on OXPHOS,
the reductive G2/M phase depends on aerobic glycolysis and
is largely independent of oxygen consumption. Hence, we
compared the phosphorylation of IF1 of HCT116 cells arrested
in G1 by incubation with the DNA-polymerase inhibitor aphidico-
lin (Figure 5C) versus that of cells arrested in G2/M by incubation
with nocodazole, a disruptor of the mitotic spindle (Figure 5C).
The results showed that most of IF1 was phosphorylated in
G1 cells, whereas dephosphorylated IF1 was present in cells
arrested in G2/M (Figure 5D). Consistently, the changes in IF1
phosphorylation nicely correlated with the relative activity of
OXPHOS and aerobic glycolysis in the different phases of theCell Repcell cycle, with dephosphorylated IF1 being concurrent with
repressed OXPHOS and an enhanced aerobic glycolysis of the
cells (Figure 5D).
IF1 and Cellular Hypoxia
Cellular hypoxia, induced either by oxygen deprivation or chem-
ically by incubation of the cells with CoCl2, promotes the arrest of
OXPHOS (OSR in Figure 6A) and triggers aerobic glycolysis (Fig-
ure 6A). Consistently, we observed the shift of IF1 toward the
dephosphorylated state in hypoxic cells (Figure 6B). The concur-
rent inhibition of both the ATP hydrolase (Figure 6C) and ATP
synthetic (Figure 6D) activities of the H+-ATP synthase by hypox-
ia was confirmed in isolated mitochondria (Figure 6C) and in per-
meabilized HCT116 cells (Figure 6D), respectively. Interestingly,
silencing of IF1 in cells treated with CoCl2 blunted the inhibition
of the hydrolase and synthetic activities of the H+-ATP synthase
(Figure S2). Moreover, incubation of the cells with CoCl2 in the
presence of Frsk enhanced both the ATPase (Figure 6C) and
synthase (Figure 6D) activities of the enzyme. Consistently, the
IF1-mediated inhibition of the ATP synthase in CoCl2-treated
cells also correlated with an enhanced binding of IF1 onto theorts 12, 2143–2155, September 29, 2015 ª2015 The Authors 2147
Figure 4. Dephosphorylation of IF1 Reprograms Energy Metabolism
HCT116 cells were treated with H89 (gray bar), PKI (open bar), db-cAMP (hatched bar), or left untreated (CRL; closed bar).
(A) The respiratory profile, the basal rate, OSR, andmaximum respiratory rates are shown. OCR, oxygen consumption rate; DNP, 2,4-dinitrophenol; ROT +ANT A,
rotenone + antimycin A.
(B) Cells transfected with control (siCRL) or siIF1 siRNA (siIF1) were treated (+) or not (-) with H89.
(C and D) In (C), the initial rates of lactate production were determined after cellular treatments. In (D), cells were transfected with control (siCRL or siC) or siIF1
siRNA (siIF1) and after treated as indicated. The silencing of IF1 was verified by western blot.
Error bars are the mean ± SEM of three experiments. *p < 0.05 when compared to CRL by Student’s t test.enzyme, as revealed by BN gels (Figure 6E), further supporting
the role of IF1 in reprogramming energy metabolism.
IF1 Is Dephosphorylated in Prevalent Human
Carcinomas
We have recently stressed the contribution of IF1 to the glyco-
lytic phenotype in some human carcinomas (Formentini et al.,
2012; Sa´nchez-Arago´ et al., 2013b; Sa´nchez-Cenizo et al.,
2010). To assess the phosphorylation status of IF1 in tumor sam-
ples from human patients, we used phosphate-affinity (Phos-
tag) PAGE and western blotting (Kinoshita et al., 2009). Consis-
tently, incubation of the samples with the phosphatase (CiP in
Figure 6F) abrogates the differences in electrophoretic migration
between phospho-IF1 (p-IF1) and IF1. Phos-tag immunoblot
analysis indicated that most colorectal carcinomas (Figure 6F),
breast adenocarcinomas (Figure 6G), and lung squamous cell2148 Cell Reports 12, 2143–2155, September 29, 2015 ª2015 The Acarcinomas (Figure 6H) and adenocarcinomas (Figure 6I) have
IF1 in its dephosphorylated state, strongly supporting a role for
IF1 as inhibitor of the H+-ATP synthase and, hence, of OXPHOS
in human cancers.
Activation of PKA Triggers the Phosphorylation and
Inactivation of IF1 in Heart In Vivo
Stimulation of cardiac b-adrenoceptors is crucial to increase
heart function under stress (Steinberg and Brunton, 2001). Their
coupling to stimulatory G proteins (Gs) triggers the activation of
adenylyl cyclase, which generates the cAMP involved in down-
stream signaling through the activation of PKA. To test in vivo
the relevance of IF1 phosphorylation, we treated mice with clen-
buterol, a b-adrenergic agonist, and assayed the phosphoryla-
tion status of IF1 in parallel with the ATP synthase and hydrolase
activities of the enzyme in isolated heart mitochondria. Otheruthors
Figure 5. Energy Demand Determines IF1 Phosphorylation
(A–D) HCT116 cells in (A), (C), and (D) and BT549 cells in (B) were treated with OL (closed bars), 2DG (open bars), aphidicolin (APHI; gray bars), or nocodazole
(NOCO; hatched bars), and the OSR, initial rates of lactate production, and the phosphorylation of IF1 were determined. The pI range of the strips and of the
focused proteins is indicated under the blots. In (C), the cell cycle of treated cells was analyzed. The histograms in (A), (B) and (D) indicate themean ± SEM of 8–10
different samples. *p < 0.05 when compared to control by Student’s t test.mice were treated with propranolol, a b-adrenergic antagonist.
Interestingly, 50% of IF1 in mouse heart is found in its
phosphorylated state (mouse 2 in Figure 7A). The administration
of clenbuterol promotes a sharp increase in the phosphorylation
of IF1 (mice 1, 4, and 5 in Figure 7A) that is abrogated by incuba-
tion of heart extracts with CiP (mice 1, 4, and 5 in Figure 7A).
Consistently, in this situation, we observed a sharp increase in
the concentration of cAMP in isolated heart mitochondria
(Figure 7B). In contrast, the administration of propanolol shifted
the phosphorylation status of IF1 toward its dephosphorylated
state (mouse 3 in Figure 7A) and had no effect on intramitochon-
drial cAMP (Figure 7B). Remarkably, a short 10-min incubation of
isolated mitochondria in the presence of the membrane-perme-
able db-cAMP triggered the rapid and complete phosphorylation
of IF1 (Figure 7C), supporting the participation of mitochondrial
PKA in the regulation of IF1 phosphorylation. Overall, these
findings support the hypothesis that, under b-adrenergic activa-
tion, when the energy demand is enhanced, most of the IF1
reserve of the cell becomes inactivated to prevent its binding
to the H+-ATP synthase in order to favor a higher output of
ATP. Consistent with this suggestion, we observed that bothCell Repthe ATP hydrolytic (Figure 7D) and synthetic (Figure 7E) activities
of the H+-ATP synthase assayed in isolated heart mitochondria
of clenbuterol-treated mice were significantly higher than that
in mitochondria of control, saline-treated mice. In agreement
with the shift toward dephosphorylated IF1 upon propranolol
administration (Figure 7A), we observed that both activities of
the H+-ATP synthasewere significantly reducedwhen compared
to those of saline-treated mice (Figures 7D and 7E).
DISCUSSION
A long-standing principle is that IF1, the intrinsically disordered
inhibitor of the H+-ATP synthase (Bason et al., 2014; Gordon-
Smith et al., 2001), is a unidirectional inhibitor of ATP hydrolysis,
having no direct effect on ATP synthesis when in the presence of
a proton motive force (Walker, 2013). However, previous data
from our laboratory obtained in cells (Formentini et al., 2012;
Sa´nchez-Arago´ et al., 2013b, 2013c), and in a mouse model
overexpressing an active IF1 in neurons (Formentini et al.,
2014), support that in vivo IF1 also inhibits the synthase activity
of the H+-ATP synthase. Herein, we demonstrate that, whenorts 12, 2143–2155, September 29, 2015 ª2015 The Authors 2149
Figure 6. Hypoxia and Cancer Trigger the Dephosphorylation of IF1
(A–D) HCT116 cells were left untreated (CRL, closed bar), treated with CoCl2 (gray bar), or subjected to oxygen deprivation (open bar). CoCl2 treatment was also
added along with H89 (hatched bar) or Frsk (dotted bar). The OSR and initial rates of lactate production (A) and the analysis of IF1 phosphorylation (B) were
determined. In (C), hydrolase activity of the H+-ATP synthase was determined in isolated mitochondria. In (D), rates of ATP production in permeabilized HCT116
cells are given. The histograms in (A), (C), and (D) indicate the mean ± SEM of three experiments.
(E) BN immunoblot of mitochondrial membranes from HCT116 cells treated with Frsk or CoCl2. The co-migration of the ATP synthase (FoF1) with IF1 is shown by
blotting with anti-b-F1-ATPase and anti-IF1 antibodies, respectively. The histogram shows the IF1/bF1 ratio of three different experiments.
(F–I) Phos-tag SDS-PAGE analysis of the phosphorylation of IF1 in human extracts of colorectal carcinomas (CRC) in (F), breast carcinomas (BC) in (G), lung
squamous cell carcinomas (LSC) in (H), and lung adenocarcinomas (LAC) in (I). Histograms represent the percentage of phospho-IF1 (p-IF1, open bars) and
dephosphorylated IF1 (IF1, closed bars) in the samples.
Bars indicate the mean ± SEM. The number of studied patients is indicated. *p < 0.05 when compared to CRL by Student’s t test.IF1 is dephosphorylated, it inhibits both the synthase and hydro-
lase activities of the enzyme, as assessed in permeabilized cells
and in isolated mitochondria from cells and mouse hearts. We
show that IF1 is subjected to reversible post-translational modi-
fication by phosphorylation, most probably through the activa-
tion of mitochondrial PKA. Mechanistically, we demonstrate
that phosphorylation of IF1 in S39 impedes its interaction with
the H+-ATP synthase, hampering in this way its potential as an
inhibitor of the enzyme. Moreover, we unveil the relevance that
the phosphorylation of IF1 has for understanding the physiolog-2150 Cell Reports 12, 2143–2155, September 29, 2015 ª2015 The Aical role that this protein plays in the mitochondrial adaptations
that require metabolic rewiring, such as in the response to an
increased demand for ATP provision by OXPHOS in vivo or in
the activation of aerobic glycolysis during progression through
the cell cycle, in hypoxia, and in human carcinomas. Overall,
the phosphorylation of IF1 acts as the molecular switch that reg-
ulates the inhibitory activity of IF1 on the synthase, hence
revealing a mechanism to coordinate metabolic activity in the
cytoplasm and inmitochondria in response to changes in cellular
signaling aimed at satisfying the fluctuating energy demand.uthors
Previous reports have described the phosphorylation of S39
and S63 of human IF1, which, in the mature protein, correspond
to S14 and S38, respectively (see Figure S1C). Herein, we show
that phosphorylation of S39/S14 determines the biological activ-
ity of the protein by preventing its interaction with the H+-ATP
synthase. Phosphorylation of IF1 is not restricted to a small frac-
tion of the protein but rather can affect the whole pool of IF1,
as revealed in different metabolic situations. IF1 has been
described as an intrinsically disordered protein (Gordon-Smith
et al., 2001), as this conformation of the inhibitor is essential
for its initial interaction with the F1-ATPase domain of the H+-
ATP synthase (Bason et al., 2014) (Figure 7F). Intrinsically dis-
ordered proteins are important components of cellular signaling,
because conformational disorder-to-order transitions mediate
biological function (Wright and Dyson, 2015) and protein phos-
phorylation is known to regulate these transitions (Bah et al.,
2015). Hence, we suggest that phosphorylation of S39/S14
might promote the folding of the intrinsically disordered IF1
and that this conformational transition would impede its capacity
to grasp and enter its binding site on F1-ATPase (Figure 7F)
(Bason et al., 2014). We cannot exclude that steric hindrance
and/or electrostatic repulsions of the phosphorylated S39/S14
could also contribute in interfering the binding of IF1. Interest-
ingly, the highly conserved S39/S14 is placed at the initiation
of the single a-helical turn that interacts with the g-subunit
(Figure 7G) (Bason et al., 2014).
The activity of PKA is involved in the phosphorylation of IF1,
triggering the activation of the synthase and hydrolase activities
of the H+-ATP synthase and thus supporting that IF1, when
bound to the enzyme, inhibits both activities (Figure 7H). The
activation of OXPHOS mediated by cAMP/PKA signaling is in
agreement with previous reports by others (Acin-Perez et al.,
2009; Di Benedetto et al., 2013; Livigni et al., 2006; Papa et al.,
2008). However, it should be noted that the physiological rele-
vance, mitochondrial substrates, and the site of PKA action are
still a matter of debate (Di Benedetto et al., 2014; Valsecchi
et al., 2013), despite PKA being described in the mitochondria
of a wide range of mammalian species (Pagliarini and Dixon,
2006). Moreover, PKA has been recently described to be associ-
ated with high-molecular-weight complexes of the inner mito-
chondrial membrane (Acı´n-Pe´rez et al., 2014). In this line, it is
well established that the activation of the b-adrenergic/adenylyl
cyclase/cAMP/PKA signaling pathway in cardiac muscle results
in the phosphorylation and activation of protein targets involved
in the provision of metabolic precursors for oxidative purposes
(Christian et al., 1969), concurrently with a raise of cytoplasmic
Ca2+ (Kamp and Hell, 2000), which is a key element for the acti-
vation of OXPHOS (Glancy and Balaban, 2012). Intracellular Ca2+
triggers the contraction of muscle fibers and is subsequently
sequestered by mitochondria (Rizzuto et al., 2012), where it
could activate the soluble adenylyl cyclase that has been shown
to be regulated by bicarbonate (Acin-Perez et al., 2009) and Ca2+
(Di Benedetto et al., 2013), building up intramitochondrial cAMP,
as we have observed in the heart mitochondria of clenbuterol-
treated mice. Since cAMP is not permeable across mitochon-
drial membranes (Di Benedetto et al., 2013) and we have
observed the rapid phosphorylation of IF1 in isolated mitochon-
dria in response to the permeable db-cAMP, we suggest thatCell Repphosphorylation of IF1, similarly to COXIV-1 (Acin-Perez et al.,
2011), could be exerted inside mitochondria by PKA or a PKA-
like enzyme (Figure 7H) (Acin-Perez et al., 2009; Di Benedetto
et al., 2014; Valsecchi et al., 2013).
In our hands, PKA is unable to phosphorylate IF1 in in vitro
assays, suggesting the requirement of additional proteins for
IF1 phosphorylation. Three major A-kinase anchor proteins
(AKAPs) targeting PKA to mitochondria have been described:
AKAP-121 (Huang et al., 1997) and WAVE-1 (Danial et al.,
2003), which tether PKA to the outer mitochondrial membrane,
and sphingosine kinase interacting protein (SKIP), which is
mainly enriched in the inner mitochondrial membrane (Means
et al., 2011). Targeting of AKAP-121 to mitochondria produces
a burst in OXPHOS (Livigni et al., 2006). Hence, we cannot rule
out that IF1 might be phosphorylated by mitochondrial PKA
assisted by as-yet-unidentified anchoring proteins. Moreover,
it is reasonable to suggest that dephosphorylation of IF1—and,
hence, the activation of its inhibitory function—might be exerted
by a mitochondrial phosphatase (Figure 7H). However, since IF1
is a mitochondrial protein with a very short half-life of 120 min
(Sa´nchez-Arago´ et al., 2013b), it is also possible that its high rate
of turnover could reestablish its potential inhibitory activity on the
H+-ATP synthase.
The primary biological role suggested for IF1 is to act as the
mitochondrial protein that, in situations that compromise the
proton motive force (hypoxia), prevents ATP hydrolysis and
the waste of biological energy (Campanella et al., 2008; Gledhill
et al., 2007; Walker, 2013) (Figure 7H). In line with this idea, the
disaggregation and activation of IF1 appear to be controlled by
the ionic state of a histidine residue (H49) that is thought to pro-
vide a pH-sensitive switch between inactive and active states
of the protein at relatively low values of intramitochondrial pH
(Cabezon et al., 2000). The mechanisms that we are now
describing in no way compromises our understanding of the
regulation of IF1 function by pH but rather amplifies it because
only dephosphorylated IF1 is able to bind the synthase and inhibit
its hydrolase activity.Moreover, it illuminates the paradox thatwe
have previously stressed regarding the high expression levels of
IF1 found in tissueswith high energy demand (brain, kidney, liver,
and heart) (Sa´nchez-Arago´ et al., 2013b; Sa´nchez-Cenizo et al.,
2010). In fact, we demonstrate a mechanism for the silencing
of the inhibitory activity of IF1 on theH+-ATP synthase (Figure 7H)
that might affect a fraction of the expressed protein in these
tissues. Indeed, the presence of the bulk of IF1 in mouse heart
in both its phospho- and dephosphorylated states offers the pos-
sibility of a reservoir for an enhanced tissue capacity of OXPHOS
in response to a burst of metabolic demand, as we have shown
after treatment of mice with clenbuterol and the subsequent
enhanced production of ATP by mitochondria (Figure 7).
Provided that dephospho-IF1 binds and inhibits the ATP syn-
thetic activity of the enzyme, the question is, what might be the
role for a fraction of inhibitory IF1 in highly demanding tissues?
One answer might be that this fraction of IF1 is being used for
the fine adjustment of the mitochondrial output of ATP. Perhaps,
although a speculation at the present stage is that the inhibition
of a fraction of the available H+-ATP synthase by IF1 might be
involved in cellular tuning by ‘‘mitohormesis’’ (Yun and Finkel,
2014). Indeed, IF1-mediated inhibition of the H+-ATP synthaseorts 12, 2143–2155, September 29, 2015 ª2015 The Authors 2151
Figure 7. In Vivo Stimulation of PKA Promotes IF1 Phosphorylation and Its Inactivation
Micewere intraperitoneally injectedwith PBS (CRL; black traces and bars), 1mg/kg clenbuterol (CLEN; red traces and bars), or 10mg/kg propranolol (PROP; blue
traces and bars).
(A) Phos-tag SDS-PAGE analysis of the phosphorylation of IF1 (p-IF1). CiP treatment of CLEN samples (green bars) were included as control. pIF1/total IF1 ratio is
shown.
(B) cAMP in isolated heart mitochondria from mice treated as indicated.
(legend continued on next page)
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has been shown to promote the production of superoxide radical
(Formentini et al., 2012; Sa´nchez-Arago´ et al., 2013b), a reactive
oxygen species (ROS) signal of mild intensity that triggers
nuclear reprogramming aimed at the activation of defensemech-
anisms to prevent cell death both in cancer cells (Formentini
et al., 2012; Sa´nchez-Arago´ et al., 2013b) and in neurons in vivo
(Formentini et al., 2014) (Figure 7H). This speculation is further
supported by the recent observations that the generation of
mitochondrial ROS (Schaar et al., 2015) and the inhibition of
the H+-ATP synthase (Chin et al., 2014) positively affect lifespan
extension, hence claiming a relevant role for IF1 and the H+-ATP
synthase in cell physiology.
EXPERIMENTAL PROCEDURES
Human Tumor Samples and Mouse Studies
Frozen tissue sections obtained from surgical specimens of untreated breast,
lung, and colon cancer patients were processed. The project was approved by
the Ethical Committee of the Universidad Auto´noma de Madrid (CEI-24-571).
For details, see the Supplemental Information. For mouse experiments, 12- to
20-week-old mice of the FVB genetic background were injected intraperitone-
ally with sterile PBS (GIBCO), 1 mg/kg clenbuterol (Sigma), or 10 mg/kg prop-
anolol hydrochloride (Sigma) and sacrificed 12 hr after.
Cell Lines, Treatments, and siRNA Silencing
Human colorectal carcinoma HCT116 cells were grown in McCoy’s 5A media.
Details for other cell lines are provided in the Supplemental Information. Cells
were treated with PKA agonists (100 mM db-cAMP or 40 mM forskolin) or
inhibitors (10 mM competitive inhibitor H89 or 1 mM PKI fragment 6–22) for
12 hr before processing. Suppression of IF1 expression in HCT116 cells was
performed using siPORT NeoFX Transfection Agent (Ambion) and a specific
small interfering RNA (siRNA) (QIAGEN S100908075) at a final concentration
of 20 nM. An inefficient siRNA sequence, Silencer Select Negative Control
#1 (Ambion), was used as a control. For hypoxic stress, cells were treated
either with 200 mM CoCl2 for 12 hr or deprived of oxygen (1% O2) for the
indicated times in a Hypoxic Workstation H35 (Don Whitley Scientific).
Dephosphorylation of proteins with CiP (New England Biolabs) was carried
out by incubation of 50 mg of cellular extracts at 37C for 1 hr with 20 U of
CiP. Protein concentration was determined using the Bradford reagent using
BSA as standard.
IF1 Mutants
Site-directed mutagenesis of IF1 to generate the phospho-mutants S27A,
S39A, and S63A and phospho-mimetic S27E, S39E, and S63E constructs
was performed with QuickChange Lightning (Agilent Technologies) using
the primers indicated in Table S1 and the pCMV-SPORT6-IF1 plasmid
(Sa´nchez-Cenizo et al., 2010).(C) Isolated mitochondria from HCT116 cells were incubated for 10 min with (+) or
IF1 identified on 2D gels.
(D) Hydrolase activity of the H+-ATP synthase in isolated mitochondria from mo
340 nm.
(E) ATP production in isolated heart mitochondria.
(F and G) In (F), side views of the a (red)-, b (yellow)-, and g (dark blue)-subunits of t
(light blue) are shown. Images of the bovine F1-(I1-60His)2 complex are taken from
System. (G) Cross-sectional side view of the central stalk (dark blue) and the b-sub
is phosphorylated in the mature human IF1 (S14) is mapped and highlighted (red s
the central stalk (dark blue).
(H) Signaling pathways (arrows) that convey on the activation of PKA (green) res
broken arrow indicates the putative activity of a phosphatase on phosphorylated
the H+-ATP synthase (yellow) and, hence, allows the synthesis of ATP. Dephosp
synthesis and hydrolysis of ATP. The fraction of dephosphorylated IF1 that is pres
H+-ATP synthase. Based on previous findings, we speculate that the IF1-mediat
Bars indicate mean ± SEM of four different mice per condition tested. *p < 0.05
Cell Rep2D and BN Gel Electrophoresis
Isoelectrofocusing (IEF) was performed with 13-cm Immobiline DryStrips of
different pH gradients (pH 3–10 L [linear], pH 3–11 NL [nonlinear], or pH
6–11 L; GE Healthcare) using an Ettan IPGPhor3 IEF unit (GE Healthcare).
For BN gels, isolated mitochondria were suspended in 50 mM Tris-HCl,
pH 7.0, containing 1 M 6-aminohexanoic acid, at a final concentration of
10 mg/ml. The membranes were solubilized by the addition of 10% digitonin.
5% Serva Blue G dye in 1 M 6-aminohexanoic acid was added to the solubi-
lized membranes. Additional details for 2D and BN gels are provided in
Supplemental Information.
Immunoblot Analysis
Details of protein fractionation on SDS-PAGE and of the antibodies used in
western blots are provided in the Supplemental Information.
Immunoprecipitation Assays
Cells were lysed on lysis buffer (50 mM Tris-HCl, pH 6.0, 150 mM NaCl, 0.5%
Nonidet P40), complete EDTA-free protease inhibitor cocktail (Roche), and
phosphatase inhibitor cocktail (Sigma). Protein from cell lysates (400 mg)
was incubated with 12 mg of the indicated antibody bound to EZ View Red
Protein G Affinity Gel at 4C.
Aerobic Glycolysis and Oxygen Consumption Rates
The oxygen consumption rates (XF24 Extracellular Flux Analyzer, Seahorse
Bioscience) and the initial rate of lactate production were determined as pre-
viously described (Sa´nchez-Cenizo et al., 2010).
Determination of the H+-ATP Synthase Activities
Mitochondria isolated from HCT116 cells or from mouse hearts were used
for the determination of the hydrolase activity of the enzyme (Formentini
et al., 2014). The ATP synthetic activity was determined in isolated mito-
chondria and in digitonin-permeabilized cells (Vives-Bauza et al., 2007).
Aliquots, taken at indicated time intervals, were precipitated with 6%
HClO4 and neutralized with 10% KOH, and the ATP content was determined
using the ATP Bioluminiscence Assay Kit (Roche) to assess the linear rate of
ATP synthesis (Mourier et al., 2014). Inhibition of the hydrolase and syn-
thase activities of the H+-ATP synthase was accomplished by the addition
of 30 mM OL.
Determination of cAMP
cAMP levels were determined in 200 mg of isolated heart mitochondrial protein
using the cAMP Direct Immunoassay Kit (Abcam).
Phosphate-Affinity PAGE Assay
Samples were resuspended in Phos-tag buffer (Wako Chemicals). To detect
phosphorylated IF1, 30 mg of the sample was loaded in 10% polyacrylamide
gels containing 80 mM Phos-tag acrylamide and 160 mM MnCl2. Gels were
transferred onto nitrocellulose membranes in the presence of 0.1 mM EDTA
and further blotted against anti-IF1.without (-) db-cAMP in the presence or absence of phosphatase inhibitors and
use heart. Where indicated, 30 mM OL (+OL) was added. A340, absorbance at
he bovine F1-ATPase and of its interaction with the 1–60 fragment of bovine IF1
Bason et al. (2014) (PDB:4TSF), created with the PyMOL Molecular Graphics
unit (yellow) interacting with the IF1 fragment (light blue). The serine residue that
phere) onto the bovine IF1 fragment. Note the close contact between S14 and
ult in the phosphorylation of the bulk of IF1 (blue rods) present in the tissue. A
IF1. The phosphorylation of IF1 (orange/blue rods) prevents its interaction with
horylated IF1 (blue rod) interacts with the H+-ATP synthase and prevents the
ent in tissues with high energy demand triggers the inhibition of a fraction of the
ed inhibition of the H+-ATP synthase contributes to signaling mitohormesis.
when compared to CRL by Student’s t test.
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Statistical Analysis
Statistical analyses were performed using a two-tailed Student’s t test. The
results shown are means ± SEM. *p < 0.05 was considered statistically
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.08.052.
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